Awadalla, Magid http://orcid.org/0000-0002-7229-0903
Golden, Doll Lauren Alexandra
Mahmood, Syed S.
Alvi, Raza M.
Mercaldo, Nathaniel D.
Hassan, Malek Z. O.
Banerji, Dahlia
Rokicki, Adam
Mulligan, Connor
Murphy, Sean P. T.
Jones-O’Connor, Maeve
Cohen, Justine V.
Heinzerling, Lucie M.
Armanious, Merna
Sullivan, Ryan J.
Damrongwatanasuk, Rongras
Chen, Carol L.
Gupta, Dipti
Kirchberger, Michael C.
Moslehi, Javid J.
Shah, Sachin P.
Ganatra, Sarju
Thavendiranathan, Paaladinesh
Rizvi, Muhammad A.
Sahni, Gagan
Lyon, Alexander R.
Tocchetti, Carlo G.
Mercurio, Valentina
Thuny, Franck
Ederhy, Stephane
Mahmoudi, Michael
Lawrence, Donald P.
Groarke, John D.
Nohria, Anju
Fradley, Michael G.
Reynolds, Kerry L.
Neilan, Tomas G.
Article History
Received: 12 December 2018
Accepted: 13 February 2019
First Online: 22 February 2019
Author’s information
: Not applicable.
: The Institutional Review Boards at each center granted a waiver of informed consent for this study.
: Not applicable.
: Dr. Mahmood has received consultancy fees from OMR Globus, Alpha Detail, and Opinion Research Team. Dr. Nohria has received research support from Amgen; and has been a consultant for Takeda Oncology. Dr. Heinzerling has received consultancy, advisory board, and speaker fees from MSD, BMS, Roche, Novartis, Amgen, and Curevac. Dr. Sullivan has been a consultant to Merck and Novartis. Dr. Moslehi has served as a consultant/advisor for Novartis, Pfizer, Bristol-Myers Squibb, Takeda/Millennium, Ariad, Acceleron, Vertex, Incyte, Rgenix, Verastem, Pharmacyclics, StemCentRx, Heat Biologics, Daiichi-Sankyo, and Regeneron. Dr. Tocchetti has received speaker fees from Alere. Dr. Groarke has received research support from Amgen. Dr. Neilan has received advisory fees from Takeda and Parexel. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.